



PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Work Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	1	Of	47	Attorney Docket Number	33769-701.831

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,631,169	05-20-1997	Lakowicz et al.	
	2.	US-5,578,461	11-26-1996	Sherwin et al.	
	3.	US-5,283,317	02-01-1994	Saifer et al.	
	4.	US-5,223,409	06-29-1993	Ladner et al.	
	5.	US-4,873,316	10-10-1989	Meade et al.	
	6.	US-4,868,103	09-19-1989	Stavrianopoulos et al.	
	7.	US-4,522,811	06-11-1985	Syntex (U.S.A.) Inc.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	8.	EP-0,264,166	04-20-1988	Integrated Genetics		
	9.	EP 3024164.0	10-20-2003	E.I. du Pont de Nemours and Co.		
	10.	WO-03-087404	10-23-2003	Novartis AG		
	11.	WO-03-063581	08-07-2003	Fred Hutchinson Cancer Research Center		
	12.	WO-02-090519	11-14-2002	Board of Regents, U. of Texas		
	13.	WO-97-42222	11-13-1997	Cyclacel Limited		
	14.	WO-96-14334	05-17-1996	U. of Dundee		
	15.	WO-96-02140	02-01-1996	Sloan-Kettering Institute of Cancer Research		
	16.	WO-94-12650	06-09-1994	Transkaryotic Therapies, Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	2	Of	47	Attorney Docket Number	33769-701.831

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	17.	WO-94-10300	05-11-1994	The General Hospital Corporation		
	18.	WO-93-09222	05-13-1993	Transkaryotic Therapies, Inc.		
	19.	WO-93-07283	04-15-1993	Boehringer Ingelheim International GMBH		
	20.	WO-93-01288	01-21-1993	Deutsches Krebsforschungszentrum		
	21.	WO-92-20791	11-26-1992	Cambridge Antibody Technology Limited		
	22.	WO-92-18619	10-29-1992	The Scripps Research Institute		
	23.	WO-92-15679	09-17-1992	Protein Engineering Corporation		
	24.	WO-92-09690	06-11-1992	Genentech, Inc.		
	25.	WO-92-01047	01-23-1992	Cambridge Antibody Technology Limited		
	26.	WO-91-17271	11-14-1991	Affymax Technologies		
	27.	WO-90-02809	03-22-1990	Protein Engineering Corporation		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	3	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	28.	AGRAWAL, D. et al., "Repression of p27 <sup>Kip1</sup> Synthesis on Platelet-Derived Growth Factor in BALB/c 3T3 Cells," Mol. Cell Biol. 16:4327-4336 (1996)	
	29.	ALEVIZOPOULOS, K. et al., "A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27 <sup>Kip1</sup> ," Embo J. 17:5987-5997 (1998)	
	30.	ALKARAIN, A. et al., "p27 Deregulation in Breast Cancer: Prognostic Significance and Implications for Therapy," J. Mammary Gland Biol. And Neoplasia 9:67-80 (2004)	
	31.	ALTSCHUL, S.F. et al., "Basic Local Alignment Search Tool," J. Mol. Biol. 215:403-410 (1990)	
	32.	ALTSCHUL, S.F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," Nucleic Acids Res. 25:3389-3402 (1997)	
	33.	AMANN, E. et al., "Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli," Gene 69:301-315 (1988)	
	34.	ARKIN, A.P. and YOUNG, D.C., "An algorithm for protein engineering: Simulations of recursive ensemble mutagenesis," PNAS USA 89:7811-7815 (1992)	
	35.	ARMENTANO, D. et al., "Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B," PNAS	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	4	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
		USA 87:6141-6145 (1990)		
	36.	ASADA, H. et al., "Grf40, A Novel Grb2 Family Member, Is Involved in T Cell Signaling through Interaction with SLP-76 and LAT," J. Exp. Med. 189:1383-1390 (1999)		
	37.	AXELROD, J.H. et al., "Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs," PNAS USA 87:5173-5177 (1990)		
	38.	BAGUI et al., "Analysis of Cyclin D3-cdk4 Complexes in Fibroblasts Expressing and Lacking p27 <sup>Kip1</sup> and p21 <sup>Cip1</sup> ," MCB20:8748-8757 (2000)		
	39.	BAGUI et al., "p27 <sup>Kip1</sup> and p21 <sup>Cip1</sup> Are Not Required for the Formation of Active D Cyclin-cdk4 Complexes," MCB23:7285-7290 (2003)		
	40.	BALDARI, C. et al., "A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1 $\beta$ in Saccharomyces cerevisiae," EMBO J. 6:229-234 (1987)		
	41.	BALTENSPERGER, K. et al., "Binding of hte Ras Activator Son of Sevenless to Insulin Receptor Substrate-1 Signaling Complexes," Science 260:1950-1952 (1993)		
	42.	BANERJI, J. et al., "A Lymphocyte-Specific Cellular Enhancer is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes," Cell 33:729-740 (1983)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/576,845	
			Filing Date	April 20, 2006	
			First Named Inventor	Ludger Hengst et al.	
			Art Unit	1652	
			Examiner Name	Not Yet Assigned	
Sheet	5	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	43.	BARTEL, P. et al., "Elimination of False Positives That Arise in Using the Two-Hybrid System," Biotechniques 14:920-924 (1993)	
	44.	BLAIN, S.W., et al., "p27 as a target for cancer therapeutics," Cancer Cell 3:111-115 (2003)	
	45.	BLAIN et al., "Differential Interaction of the Cyclin-dependent Kinase (Cdk) Inhibitor p27 <sup>Kip1</sup> with Cyclin A-Cdk2 and Cyclin D2-Cdk4," JBC 272:25863-25872 (1997)	
	46.	BLOOM, J. and PAGANO, M., "Deregulated degradation of the cdk inhibitor p27 and malignant transformation," Semin. Cancer Biol. 13:41-47 (2003)	
	47.	BOEHM, M. et al., "A growth factor-dependent nuclear kinase phosphorylates p27 <sup>Kip1</sup> and regulates cell cycle progression," Embo J. 21:3390-3401 (2002)	
	48.	BONTEMPO, F.A. et al., "Liver Transplantation in Hemophilia A," Blood 69:1721-1724 (1987)	
	49.	BOUCHARD, C. et al., "Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27," Embo J. 18:5321-5333 (1999)	
	50.	BOURETTE, R.P. et al., "Mona, a novel hematopoietic-specific adaptor interacting with the macrophage colony-stimulating factor receptor, is implicated in	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Lüdger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	6	Of	47	Attorney Docket Number 33769-701.831	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
		monocyte/macrophage development," Embo J. 17:7273-7281 (1998)		
	51.	BOYLE, W.J. et al., "Phosphopeptide Mapping and Phosphoamino Acid Analysis by Two-Dimensional Separation on Thin-Layer Cellulose Plates,: Methods Enzymol. 201:110-149 (1991)		
	52.	BRANDEIS, M. and HUNT, T., "The proteolysis of mitotic cyclins in mammalian cells persists from the end of mitosis until the onset of S phase," Embo J. 15:5280-5289 (1996)		
	53.	BRESLAUER, K.J. et al., "Predicting DNA duplex stability from the base sequence," PNAS USA 83:3746-3750 (1986)		
	54.	BROTHERTON, D.H. et al., "Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19 <sup>INK4d</sup> ," Nature 395:244-250 (1998)		
	55.	BROWN, J.P. et al., "Bypass of Senescence After Disruption of p21 <sup>CIP1/WAF1</sup> Gene in Normal Diploid Human Fibroblasts," Science 277:831-834 (1997)		
	56.	BRUGAROLAS, J. et al., "Radiation-induced cell cycle arrest compromised by p21 deficiency," Nature 377:552-557 (1995)		
	57.	BYRNE, G.W. and RUDDLE, F.H., "Multiplex gene regulation: A two-tiered approach		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	7	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		to transgene regulation in transgenic mice," PNAS USA 86:5473-5477 (1989)	
	58.	CALAME, K. and EATON, S., "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci," Adv. Immunol. 43:235-275 (1988)	
	59.	CAMPER, S.A. and TILGHMAN, S.M., "Postnatal repression of the $\alpha$ -fetoprotein gene is enhancer dependent," Genes Dev. 3:537-546 (1989)	
	60.	CANTLEY, L.C. and NEEL, B.G., "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway," PNAS USA 96:4240-4245 (1999)	
	61.	CARELL et al., "A Novel Procedure for the Synthesis of Libraries Containing Small Organic Molecules," Angew. Chem. Int. Ed. Engl. 33:2059-2061 (1994)	
	62.	CARNERO, A. and HANNON, G.J., "The INK4 Family of CDK Inhibitors," Curr. Top. Microbiol. Immunol. 227:43-55 (1998)	
	63.	CARRANO, A.C. et al., "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27," Nat. Cell Biol. 1:193-199 (1999)	
	64.	CHAMOVITZ, D.A. and SEGAL, D., "JAP1/CSN5 and the COP9 signalosome," Embo Rep. 2:96-101 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	8	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	65.	CHAN, F.K. et al., "Identification of Human and Mouse p19, a Novel CDK4 and CDK6 Inhibitor with Homology to p16 <sup>ink4</sup> ," Mol. Cell Biol. 15:2682-2688 (1995)	
	66.	CHELLAPPAN, S.P. et al., "Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development," Curr. Top. Microbiol. Immunol. 227:57-103 (1998)	
	67.	CHEN, P. and SEGIL, N., "p27 <sup>Kip1</sup> links cell proliferation to morphogenesis in the developing organ of Corti," Development 126:1581-1590 (1999)	
	68.	CHENG, M. et al., "The p21 <sup>Cip1</sup> and p27 <sup>Kip1</sup> CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts," EMBO J. 18:1571-1583 (1999)	
	69.	CHO, C.Y. et al., "An Unnatural Biopolymer," Science 261:1303-1305 (1993)	
	70.	CIARALLO, S. et al., "Altered p27 <sup>Kip1</sup> Phosphorylation, Localization, and Function in Human Epithelial Cells Resistant to Transforming Growth Factor $\beta$ -Mediated G <sub>1</sub> Arrest," Mol. Cell Biol. 22:2993-3002 (2002)	
	71.	CLARET, F.X. et al., "A new group of conserved coactivators that increase the specificity of AP-1 transcription factors," Nature 383:453-457 (1996)	
	72.	CLURMAN, B.E. et al., "Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation," Genes Dev. 10:1979-1990	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	9	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		(1996)	
	73.	COATS, S. et al., "Requirement of p27 <sup>Kip1</sup> for Restriction Point Control of the Fibroblast Cell Cycle," Science 272:877-880 (1996)	
	74.	COLE, ed., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <u>Monoclonal Antibodies and Cancer Therapy</u> , Alan R. Liss, Inc. 1985, pp. 77-96	
	75.	COUTTS, M. et al., "v-Abl utilizes multiple mechanisms to drive G1/S progression in fibroblasts," Oncogene 19:801-809 (2000)	
	76.	CRUIKSHANK, W.W. et al., "A Lipidated Anti-Tat Antibody Enters Living Cells and Blocks HIV-1 Viral Replication," J. Acquired Immune Deficiency Syndromes & Human Retrovirology 14:193-203 (1997)	
	77.	CULL, M.G. et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," PNAS USA 89:1865-1869 (1992)	
	78.	CWIRLA, S.E. et al., "Peptides on phage: A vast library of peptides for identifying ligands," PNAS 87:6378-6382 (1990)	
	79.	DEININGER, M.W. et al., "The molecular biology of chronic myeloid leukemia," Blood 96:3343-3356 (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	10	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	80.	DELAGRAVE, S. et al., "Recursive ensemble mutagenesis," Prot. Eng. 6:327-331 (1993)	
	81.	DENG, C. et al., "Mice Lacking p21 <sup>CIP1/WAF1</sup> Undergo Normal Development, but Are Defective in G1 Checkpoint Control," Cell 82:675-684 (1995)	
	82.	DENHARDT, D.T. in STEIN, G.S. et al., eds., "Signal Transduction Pathways and Regulation of the Mammalian Cell Cycle: Cell Type-Dependent Integration of External Signals," <u>The Molecular Basis of Cell Cycle And Growth Control</u> , Wiley & Sons, 1999, pp. 225-304	
	83.	DEVLIN, J.J. et al., "Random Peptide Libraries: A Source of Specific Protein Binding Molecules," Science 249:404-406 (1990)	
	84.	DEWITT, S.H. et al., "Hsc70 Regulates Accumulation of Cyclin D1 and Cyclin D1-Dependent Protein Kinase," PNAS USA 90:6909-6913 (1993)	
	85.	DIEHL et al., "Hsc70 Regulates Accumulation of Cyclin D1 and Cyclin D-1-Dependent Protein Kinase," MCB 23:1764-1774 (2003)	
	86.	DIEHL, J.A. et al., "Glycogen synthase kinase-3 $\beta$ regulates cyclin D1 proteolysis and subcellular localization," Genes Dev. 12::3499-3511 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	11	Of	47	Attorney Docket Number 33769-701.831	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	87.	DIEHL, J.A. et al., "Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway," BCR-ABL independGenes Dev. 11:957-972 (1997)	
	88.	DONATO, N.J. et al., "BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571," Blood 101:690-698 (2003)	
	89.	DRAETTA, G. et al., "cdc2 Protein Kinase Is Complexed with Both Cyclin A and B: Evidence for Proteolytic Inactivation of MPF," Cell 56:829-838 (1989)	
	90.	DRUKER et al., "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia," N. Engl. J. Med. 344:1031-1037 (2001)	
	91.	DRUMM, M.L. et al., "Correction of the Cystic Fibrosis Defect in Vitro by Retrovirus-Mediated Gene Transfer," Cell 62:1227-1233 (1990)	
	92.	DU, M. et al., "Cloning and Expression Analysis of a Novel Salicylate Suppressible Gene, Hs-CUL-3, a Member of Cullin/Cdc53 Family," J. Biol. Chem. 273:24289-24292 (1998)	
	93.	DUCLOS, B. et al., "Chemical Properties and Separation of Phosphoamino Acids by Thin-Layer Chromatography and/or Electrophoresis," Methods Enzymol. 201:10-21 (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	12	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	94.	DULIC, V. et al., "p53-Dependent Inhibition of Cyclin-Dependent Kinase Activities in Human Fibroblasts during Radiation-Induced G1 Arrest," Cell 76:1013-1023 (1994)	
	95.	DULIC, V. et al., "Association of Human Cyclic E with a Periodic G <sub>1</sub> -S Phase Protein Kinase," Science 257:1958-1961 (1992)	
	96.	DURAND, B. et al., "Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation," EMBO J. 16:306-317 (1997)	
	97.	DYSON, N., "The regulation of E2F by pRB-family proteins," Genes Dev. 12:2245-2262 (1998)	
	98.	ECKERSKORN, C. and LOTTSPEICH, F., "Combination of two-dimensional electrophoresis with microsequencing and amino acid composition analysis: Improvement of speed and sensitivity in protein characterization," Electrophoresis 11:554-561 (1990)	
	99.	EDLUND, T. et al., "Cell-Specific Expressio of the Rat Insulin Gene: Evidence for Role of Two Distinct 5' Flanking Elements," Science 230:912-916 (1985)	
	100.	EKHOLM, S.V. et al., "Accumulation of Cyclin E Is Not a Prerequisite for Passage through the Restriction Point," Mol. Cell Biol. 21:3256-3265 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	13	Of	47	Attorney Docket Number	.33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	101.	EKHOLM, S.V. and REED, S.I., "Regulation of G <sub>1</sub> cyclin-dependent kinases in the mammalian cell cycle," Curr. Opin. Cell Biol. 12:676-684 (2000)	
	102.	EL-DEIRY, W.S. et al., "WAF1/CIP1 Is Induced in p53-mediated G <sub>1</sub> Arrest and Apoptosis," Cancer Res. 54:1169-1174 (1994)	
	103.	EL-DEIRY, W.S. et al., "WAF1, a Potential Mediator of p53 Tumor Suppression," Cell 75:817-825 (1993)	
	104.	ERB, E. et al., "Recursive deconvolution of combinatorial chemical libraries," PNAS USA 91:11422-11426 (1994)	
	105.	FEAKINS, R.M. and GHAFAR, A.H., "p27 <sup>Kip1</sup> Expression Is Reduced in Pancreatic Carcinoma but Has Limited Prognostic Value," Hum. Pathol. 34:385-390 (2003)	
	106.	FELICI, F. et al., "Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Exposition Vector," Mol. Biol. 222:301-310 (1991)	
	107.	FERO, M.L. et al., "The murine gene p27 <sup>Kip1</sup> is haplo-insufficient for tumour suppression," Nature 396:177-180 (1998)	
	108.	FERO, M.L. et al., "A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 <sup>Kip1</sup> -Deficient Mice," Cell	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	14	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		85:733-744 (1996)	
	109.	FINK, J.K. et al., "Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease," PNAS USA 87:2334-2338 (1990)	
	110.	FODOR, S.P. et al., "Multiplexed biochemical assays with biological chips," Nature 364:555-556 (1993)	
	111.	FUCHS, P. et al., "Targeting Recombinant Antibodies to the Surface of Escherichia Coli: Fusion to a Peptidoglycan Associated Lipoprotein," Bio/Technology 9:1370-1372 (1991)	
	112.	FURUNO, N. et al., "Human Cyclin A Is Required for Mitosis until Mid Prophase," J. Cell Biol. 147:295-306 (1999)	
	113.	GALE, N.W. et al., "Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras," Nature 363:88-92 (1993)	
	114.	GALLOP, M.A. et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries," J. Med. Chem. 37:1233-1251 (1994)	
	115.	GARDNER, L.B. et al., "Hypoxia Inhibits G <sub>i</sub> /S Transition through Regulation of p27	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	15	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Expression," J. Biol. Chem. 276:7919-7926 (2001)	
	116.	GARTEL, A.L. and TYNER, A.L., "Transcriptional Regulation of the p21 <sup>(WAF1/CIP1)</sup> Gene," Exp. Cell Res. 246:280-289 (1999)	
	117.	GESBERT, F. et al., „BCR/ABL Regulates Expression of th Cyclin-dependent Kinase Inhibitor p27 <sup>Kip1</sup> through the Phosphatidylinositol 3-Kinase/AKT Pathway," J. Biol. Chem. 275:39223-39230 (2000)	
	118.	GIRARD, F. et al., "Cyclin A Is Required for the Onset of DNA Replication in Mammalian Fibroblasts," Cell 67:1169-1179 (1991)	
	119.	GOEDDEL, ed., "Systems for Heterologous Gene Expression," <u>Methods in Enzymology: Gene Expression Technology</u> Vol. 185, Academic Press, San Diego, CA 1991, pp. 3-7	
	120.	GOTTESMAN in "Minimizing Proteolysis in Escherichia coli: Genetic Solutions," <u>Methods in Enzymology: Gene Expression Technology</u> , Vol. 185, Academic Press, San Diego, CA 1990, pp.119-128	
	121.	GRAFF, J.R. et al., "Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27 <sup>Kip1</sup> Expression," J. Biol. Chem. 275:24500-24505 (2000)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	16	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	122.	GRIFFITHS, A.D. et al., "Human anti-self antibodies with high specificity from phage display libraries," EMBO J. 12:725-734 (1993)		
	123.	GU, Y. et al., "Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit," Nature 366:707-710 (1993)		
	124.	GUO, K. et al., "MyoD-Induced Expression of p21 Inhibits Cyclin-Dependent Kinase Activity upon Myocyte Terminal Differentiation," Mol. Cell Biol. 15:3823-3829 (1995)		
	125.	HAGE, D.S. and TWEED, S.A., "Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions," J. Chromatogr. B. Biomed. Sci. Appl. 699:499-525 (1997)		
	126.	HAGTING, A. et al., "Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal," Curr. Biol. 9:680-689 (1999)		
	127.	HALEVY, O. et al., "Correlation of Terminal Cell Cycle Arrest of Skeletal Muscle with Induction of p21 by MyoD," Science 267:1018-1021 (1995)		
	128.	HAMAGUCHI, T. et al., "RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G <sub>1</sub> phase," FEBS Lett. 372:54-58 (1995)		
	129.	HANNON, G.J. and BEACH, D., "p15INK4B is a potential effector of TGF- $\beta$ -induced		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	17	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
		cell cycle arrest," Nature 371:257-261 (1994)			
	130.	HARA, T. et al., "Degradation of p27 <sup>Kip1</sup> at the G0-G1 Transition Mediated by a Skp2-independent Ubiquitination Pathway," J. Biol. Chem. 276:48937-48943 (2001)			
	131.	HARDER, K.W. et al., "Gain- and Loss-of-Function Lyn Mutant Mice Define a Critical Inhibitory Role for Lyn in the Myeloid Lineage," Immunity 15:603-615 (2001)			
	132.	HARPER, J.W. et al., "Inhibition of Cyclin-dependent Kinases by p21," Mol. Biol. Cell 6:387-400 (1995)			
	133.	HARPER, J.W. et al., "The p21 Cdk-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases," Cell 75:805-816 (1993)			
	134.	HARTL, F.U., "Molecular chaperones in cellular protein folding," Nature 381:571-579 (1996)			
	135.	HAY, B.N. et al., "Bacteriophage cloning and Escherichia coli expression of a human IgM Fab," Hum. Antibod. Hybridomas 3:81-85 (1992)			
	136.	HEEGARD, N.H., "Capillary electrophoresis for the study of affinity interactions," J. Mol. Recognit. 11:141-148 (1998)			
	137.	HELMBRECHT, K. et al., "Chaperones in cell cycle regulation and mitogenic signal			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	18	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
		transduction: a review," Cell Prolif. 33:341-365 (2000)			
	138.	HENGST, L. and REED, S.I., "Inhibitors of the Cip/Kip Family, Curr. Top. Microbiol. Immunol. 227:25-41 (1998)			
	139.	HENGST, L. et al., "Complete inhibition of Cdk/cyclin by one molecule of p21 <sup>Cip1</sup> ," Genes Dev. 12:3882-3888 (1998)			
	140.	HENGST, L. and REED, S.I., "Translational Control of p27 <sup>Kip1</sup> Accumulation During the Cell Cycle," Science 271:1861-1864 (1996)			
	141.	HENGST, L. et al., "A cell cycle-regulated inhibitor of cyclin-dependent kinases," PNAS USA 91:5291-5295 (1994)			
	142.	HIBBS, M.L. and DUNN, A.R., "Lyn, a src-like Tyrosine Kinase," Int. J. Biochem. Cell Biol. 29:397-400 (1997)			
	143.	HIRAI, H. et al., "Novel INK4 Proteins, p19 and p18, Are Specific Inhibitors of the Cyclin D-Dependent Kinases CDK4 and CDK6," Mol. Cell Biol. 15:2672-2681 (1995)			
	144.	HIRAMA, T. and KOEFFLER, H.P., "Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer," Blood 86:841-854 (1995)			
	145.	HOHFELD, J. et al., "From the cradle to the grave: molecular chaperones that may			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	19	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		choose between folding and degradation," EMBO Rep. 2:885-890 (2001)	
	146.	HOUGHTEN, R.A. et al., "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," Biotechniques 13:412-421 (1992)	
	147.	HOWARD, A. and PELC, S.R., "Nuclear Incorporation of P32 as Demonstrated by Autoradiographs," Exp. Cell Res. 2:178-187 (1951)	
	148.	HUETTNER, C.S. et al., "Reversibility of acute B-cell leukaemia induced by BCR-ABL1," Nat. Genet. 24:57-69(2000)	
	149.	HUSE, W.D. et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281 (1989)	
	150.	IKE, Y. et al., "Solid phase synthesis of polynucleotides. VIII. Synthesis of mixed oligodeoxyribonucleotides by the phosphotriester solid phase method," Nucleic Acid Res. 11:477-488 (1983)	
	151.	ILYIN, G.P. et al., "cDNA Cloning and Expression Analysis of New Members of the Mammalian F-Box Protein Family," Genomics 67:40-47 (2000)	
	152.	INOUE, T. et al., "Sp1 and NF-Y Synergistically Mediate the Effect of Vitamin D3 in the p27 <sup>Kip1</sup> Gene Promoter That Lacks Vitamin D Response Elements," J. Biol. Chem. 274:32309-32317 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	20	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	153.	ISHIDA, N. et al., "Phosphorylation at Serine 10, a Major Phosphorylation Site of p27 <sup>Kip1</sup> , Increases Its Protein Stability," J. Biol. Chem. 275:25146-25154 (2000)	
	154.	ITAKURA, K. et al., "Synthesis and use of synthetic oligonucleotides," Annu. Rev. Biochem. 53:323-356 (1984)	
	155.	ITAKURA, K. et al., "Expression in Escherichia coli of a Chemically Synthesized Gene for the Hormone Somatostatin," Science 198:1056-1063 (1977)	
	156.	IWABUCHI, K. et al., "Use of the two-hybrid system to identify the domain of p53 involved in oligomerization," Oncogene 8:1693-1696 (1993)	
	157.	JANSEN-DURR, P. et al., "Differential modulation of cyclin gene expression by MYC," PNAS USA 90:3685-3689 (1993)	
	158.	JIANG, Y. et al., "Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity," PNAS USA 97:10538-10543 (2000)	
	159.	JOHNSON, D. et al., "Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence," Oncogene 16:2017-2028 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/576,845	
			Filing Date	April 20, 2006	
			First Named Inventor	Ludger Hengst et al.	
			Art Unit	1652	
			Examiner Name	Not Yet Assigned	
Sheet	21	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	160.	JONULEIT, T. et al., "Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines," Blood 96:1933-1999 (2000)		
	161.	KALDIS, P., "The cdk-activating kinase (CAK): from yeast to mammals," Cell Mol. Life Sci. 55:284-296 (1999)		
	162.	KAMIJO, T. et al., "Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 <sup>ARF</sup> ," Cell 91:649-659 (1997)		
	163.	KARLIN, S. and ALTSCHUL, S.F., "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," PNAS USA 87:2264-2268 (1990)		
	164.	KARLIN, S. and ALTSCHUL, S.F., "Applications and statistics for multiple high-scoring segments in molecular sequences," PNAS USA 90:5873-5877 (1993)		
	165.	KATO, G. and MAEDA, "Neuron-specific Cdk5 Kinase Is Responsible for Mitosis-Independent Phosphorylation of c-Src at Ser75 in Human Y79 Retinoblastoma Cells," S., J. Biochem. (Tokyo) 126:957-961 (1999)		
	166.	KAUFMAN, R.J. et al., "Translational efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells," EMBO J. 6:187-193 (1987)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	22	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	167.	KAWAMATA, N. et al., "Molecular Analysis of the Cycin-dependent Kinase Inhibitor Gene p27/Kip1 in Huma Malignancies," Cancer Res. 55:2266-2269 (1995)		
	168.	KESSEL, M. and GRUZZ, P., "Murine Development Control Genes," Science 249:374-379 (1990)		
	169.	KEYOMARSI, K. et al., "Synchronization of Tumor and Normal Cells from G1 to Multiple Cell Cycles by Lovastatin," Cancer Res. 51:3602-3609 (1991)		
	170.	KIPREOS, E.T. et al., "cul-1 Is Required for Cell Cycle Exit in C. elegans and Identifies a Novel Gene Family," Cell 85:829-839 (1996)		
	171.	KIYOKAWA, H. et al., "Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 <sup>Kip1</sup> ," Cell 85:721-732 (1996)		
	172.	KNOBLICH, J.A. and LEHNER, C.F., "Synergistic action of Drosophila cyclins A and B during the G <sub>2</sub> -M transition," EMBO J. 12:65-74 (1993)		
	173.	KNUDSON, A.G. JR., "Mutation and Cancer: Statistical Study of Retinoblastoma," PNAS USA 68:820-823 (1971)		
	174.	KOEPP, D.M. et al., "Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCF <sup>Fbw7</sup> Ubiquitin Ligase," Science 294:173-177 (2001)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	23	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	175.	KOHDA, D. et al., "Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2," Structure 2:1029-1040 (1994)	
	176.	KOHLER, G. and MILSTEIN, C., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature 256:495-497 (1975)	
	177.	KOZBOR et al., "The production of monoclonal antibodies form human lymphocytes," Immunol. Today 4:72 (1983)	
	178.	KREK, W., "Proteolysis and the G <sub>1</sub> -S transition: the SCF connection," Curr. Opin. Genet. Dev. 8:36-42 (1998)	
	179.	KRIWACKI, R.W. et al., "Probing protein structure using biochemical and biophysical methods. Proteolysis, matrix-assisted laser desorption/ionization mass spectrometry, high-performance liquid chromatography and size-exclusion chromatography of p21 <sup>Waf1/Cip1/Sdi1</sup> ," Chromatogr. A. 777:23-30 (1997)	
	180.	KRIWACKI, R.W. et al., "Structural studies of p21 <sup>Waf1/Cip1/Sdi1</sup> in the free and Cdk2-bound state: Conformational disorder mediates binding diversity," PNAS USA 93:11504-11509 (1996)	
	181.	KURJAN, J. and HERSKOWITZ, I., "Structure of a Yeast Pheromone Gene (MF $\alpha$ ): A Putative $\alpha$ -Factor Precursor Contains Four Tandem Copies of Mature $\alpha$ -Factor," Cell 30:933-943 (1982)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/576,845	
			Filing Date	April 20, 2006	
			First Named Inventor	Ludger Hengst et al.	
			Art Unit	1652	
			Examiner Name	Not Yet Assigned	
Sheet	24	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	182.	LABAER, J. et al., "New functional activites for the p21 family of CDK inhibitors," Genes Dev. 11:847-862 (1997)	
	183.	LACY, E.R. et al., "p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding," Nat. Struct. Mol. Biol. 11:358-364, Epub 2004 Mar 14 (2004)	
	184.	LAEMMLI, U.K., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," Nature 227:680-685 (1970)	
	185.	LAM, K.S., "Application of combinatorial library methods in cancer research and drug discovery," Anticancer Drug Des. 12:145-167 (1997)	
	186.	LAM, K.S. et al., "A new type of synthetic peptide library for identifying ligand-binding activity," Nature 354:82-84 (1991)	
	187.	LAW, P.K. et al., "Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy," Lancet 336:114-115 (1990)	
	188.	LEE, M.H. et al., "Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution," Genes Dev. 9:639-649 (1995)	
	189.	LEVINE, A.J., "p53, the Cellular Gatekeeper for Growth and Division," Cell 88:323-	

Examiner Signature	Date Considered	
--------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	25	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		331 (1997)	
	190.	LI, J. et al., "Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation," PNAS USA 94:502-507 (1997)	
	191.	LI, N. et al., "Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling," Nature 363:85-88 (1993)	
	192.	LI, S. et al., "Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling," EMBO J. 20:6793-6804 (2001)	
	193.	LI, Y. et al., "Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21," Oncogene 9:2261-2268 (1994)	
	194.	LINDER, M.W. et al., "Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency," Clin.Chem. 43:254-266 (1997)	
	195.	LIU, M. et al., "Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937," Genes Dev. 10:142-153 (1996)	
	196.	LOCKHART, D.J. et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," Nat. Biotechnol. 14:1675-1680 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	26	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	197.	LOWENHEIM, H. et al., "Gene disruption of p27 <sup>Kip1</sup> allows cell proliferation in the postnatal and adult organ of Corti," PNAS USA 96:4084-4088 (1999)		
	198.	LOWENSTEIN, E.J. et al., "The SH2 and SH3 domain-Containing Protein GRB2 Links Receptor Tyrosine Kinases to ras Signaling," Cell 70:431-442 (1992)		
	199.	LUCKOW, V.A. and SUMMERS, M.D., "High Level Expression of Nonfused Foreign Genes with Autographa californica Nuclear Polyhedrosis Virus Expression Vectors," Virology 170:31-39(1989)		
	200.	LUKAS, C. et al., "Accumulation of cyclin B1 requires cyclin F and cyclin-A-dependent nonarrangement of the aphase-promoting complex," Nature 401:815-818 (1999)		
	201.	LUNDBERG, A.S. et al., "Genes involved in senescence and immortalization," Curr. Opin. Cell Biol. 12:705-709 (2000)		
	202.	MACLEOD, K.F. et al., "p53-Dependent and independent expression of p21 during cell growth, differentiation, and DNA damage," Genes Dev. 9:935-944 (1995)		
	203.	MADURA, K. et al., "N-recognin/Ubc2 Interactions in the N-end Rule Pathway," J. Biol. Chem. 268:12046-12054 (1993)		
	204.	MAL, A. et al., "Inactivation of p27 <sup>Kip1</sup> by the viral E1A oncoprotein in TGFβ-cells,"		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	27	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Nature 380:262-265 (1996)	
	205.	MALEK, N.P. et al., "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27 <sup>Kip1</sup> in G1 and S phase," Nature 413:323-327 (2001)	
	206.	MARTIN-CABALLERO, J. et al., "Tumor Susceptibility of p21 <sup>Waf1/Cip1</sup> -deficient Mice," Cancer Res. 61:6234-6238 (2001)	
	207.	MATSUOKA, S. et al., "Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57 <sup>KIP2</sup> , on chromosome 11p15," PNAS USA 93:3026-3030 (1996)	
	208.	MATSUOKA, S. et al., "p57KIP2, a structurally distinct member of the p21 <sup>CIP1</sup> Cdk inhibitor family, is a candidate tumor suppressor gene," Genes Dev. 9:650-662 (1995)	
	209.	MATSUSHIME, H. et al., "Identification and Properties of an Atypical Catalytic Subunit (p34 <sup>PSK-J3/cdk4</sup> ) for Mammalian D Type G1 Cyclins," Cell 71:323-334 (1992)	
	210.	MCGRAW, R.A. et al., "Sequence-Dependent Oligonucleotide-Target Duplex Stabilities: Rules from Empirical Studies with a Set of Twenty-Mers," BioTechniques 8:674-678 (1990)	
	211.	MILLARD, S.S. et al., "Enhanced Ribosomal Association of p27 <sup>Kip1</sup> mRNA Is a Mechanism Contributing to Accumulation during Growth Arrest," J. Biol. Chem. 272:7093-7098 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	28	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	212.	MILNER, N. et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," Nat. Biotechnol. 15:537-541 (1997)	
	213.	MOELLER, S.J. et al., "p27 <sup>Kip1</sup> Inhibition of GRB2-SOS Formation Can Regulate Ras Activation," Mol. Cell Biol. 23:3735-3752 (2003)	
	214.	MOLINARI, M. et al., "Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis," EMBO Rep. 1:71-79 (2000)	
	215.	MONTAGNOLI, A. et al., "Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation," Genes Dev. 13:1181-1189 (1999)	
	216.	MORGAN, D.O., "Cyclin-Dependent Kinases: Engines, Clocks, and Microprocessors," Annu. Rev. Cell Dev. Biol. 13:261-291 (1997)	
	217.	MORGAN, D.O. et al., "Mitosis-Specific Phosphorylation of p60 <sup>c-src</sup> by p34 <sup>cdc2</sup> -Associated Protein Kinase," Cell 57:775-786 (1989)	
	218.	MORGAN, J.E. et al., "Normal Myogenic Cells from Newborn Mice Restore Normal Histology to Degenerating Muscles of the mdx Mouse," J. Cell Biol. 111:2437-2449 (1990)	
	219.	MORIMOTO, M. et al., "Modification of Cullin-1 by Ubiquitin-like Protein Nedd8 Enhances the Activity of SCF <sup>Skp2</sup> toward p27 <sup>Kip1</sup> ," Biochem. Biophys. Res. Commun.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	29	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
		270:1093-1096 (2000)		
	220.	MOROSETTI, R. et al., "Alterations of the p27 <sup>KIP1</sup> Gene in Non-Hodgkin's Lymphomas and Adult T-Cell Leukemia/Lymphoma," Blood 86:1924-1930 (1995)		
	221.	MOU, S. and LINNEKIN, D., "Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells," Biochem. J. 342:163-170 (1999)		
	222.	MUISE-HENDRICKS, R.C. et al., "Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway," J. Biol. Chem. 273:29864-29872 (1998)		
	223.	MULLER, D. et al., "Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60," EMBO J. 19:2168-2180 (2000)		
	224.	MULLER, D. et al., "Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes," Oncogene 15:2561-2576 (1997)		
	225.	MURATA, S. et al., "CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein," EMBO Rep 2:1133-1138 (2001)		
	226.	NAGAHARA, H. et al., "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27 <sup>Kip1</sup> induces cell migration," Nat. Med. 4:1449-1452 (1998)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	30	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	227.	NAKAMURA, S. et al., "73-kDa Heat Shock Cognate Proteins Interacts Directly with P27 <sup>Kip1</sup> , a Cyclin-Dependent Kinase Inhibitor, during G1/S Transition," Biochem. Biophys. Res. Commun. 257:340-343 (1999)	
	228.	NAKAYAMA, K. et al., "Mice Lacking p27Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors," Cell 85:707-720 (1996)	
	229.	NARANG, "DNA Synthesis," Tetrahedron 39:3-22 (1983)	
	230.	NGUYEN, H. et al., "Cell-Free Degradation of p27 <sup>Kip1</sup> , a G1 Cyclin-Dependent Kinase Inhibitor, Is Dependent on CDK2 Activity and the Proteasome," Mol. Cell Biol. 19:1190-1201 (1999)	
	231.	NODA, A. et al., "Cloning of Senescent Cell-Derived Inhibitors of DNA Synthesis Using an Expression Screen," Exp. Cell Res. 211:90-98 (1994)	
	232.	O'HAGAN, R.C. et al., "Myc-enhanced expression of Cull1 promotes ubiquitin-dependent proteolysis and cell cycle progression," Genes Dev. 14:2185-2191 (2000)	
	233.	OHTSUBO, M. et al., "Human Cyclin E, a Nuclear Protein Essential for the G1-to-S Phase Transition," Mol. Cell Biol. 15:2612-2624 (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	31	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	234.	OLASHAW ETAL, "Cell Cycle Control," Cell Cycle 3:263-264 (2004)	
	235.	PAGANO, M. et al., "Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27," Science 269:682-685 (1995)	
	236.	PAGANO, M. et al., "Cyclin A is required at two points in the human cell cycle," EMBO J. 11:961-971 (1992)	
	237.	PALMER, T.D. et al., "Production of Human Factor IX in Animals by Genetically Modified Skin Fibroblast: Potential Therapy for Hemophilia B," Blood 73:438-445 (1989)	
	238.	PANTOJA, C. and SERRANO, M., "Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras," Oncogene 18:4974-4982 (1999)	
	239.	PARDEE, A.B., "G1 Events and Regulation of Cell Proliferation," Science 246:603-608 (1989)	
	240.	PARDEE, A.B., "A Restriction Point for Control of Normal Animal Cell Proliferation," PNAS USA 71:1286-1290 (1974)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	32	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	241.	PARKER, S.B. et al., "p53-Independent Expression of p21 <sup>Cip1</sup> in Muscle and Other Terminally Differentiating Cells," Science 267:1024-1027 (1995)	
	242.	PARTRIDGE, T.A. et al., "Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts," Nature 337:176-179 (1989)	
	243.	PATTON, E.E. et al., "Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis," Trends Genet. 14:236-243 (1998)	
	244.	PAVLETICH, N.P., "Mechanisms of Cyclin-dependent Kinase Regulation: Structures of Cdk's, their Cyclin Activators, and Cip and INK4 Inhibitors," J. Mol. Biol. 287:821-828 (1999)	
	245.	PEARSON, W.R. and LIPMAN, D.J., "Improved tools for biological sequence comparison," PNAS USA 85:2444-2448 (1988)	
	246.	PEREZ-ROGER, I. et al., "Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27 <sup>Kip1</sup> binding to newly formed complexes," Oncogene 14:2373-2381 (1997)	
	247.	PHILIPP, A. et al., "Repression of Cyclin D1: a Novel Function of MYC," Mol. Cell Biol. 14:4032-4043 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	33	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	248.	PIETENPOL, J.A. et al., "Assignment of the Human p27 <sup>Kip1</sup> Gene to 12p13 and Its Analysis in Leukemias," Cancer Res. 55:11206-1210 (1995)		
	249.	PINES, J. and RIEDER, C.L., "Re-staging mitosis: a contemporary view of mitotic progression," Nat. Cell Biol. 3:E3-E6 (2001)		
	250.	PINES, J. and HUNTER, T., "Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B," Nature 346:760-763 (1990)		
	251.	PINKERT, C.A. et al., "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes Dev. 1:268-277 (1987)		
	252.	PLANAS-SILVA, M.D. and WEINBERG, R.A., "The restriction point and control of cell proliferation," Curr. Opin. Cell Biol. 9:768-772 (1997)		
	253.	PLATTNER, R. et al., "c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF," Genes Dev. 13:2400-2411 (1999)		
	254.	POLYAK, K. et al., "p27 <sup>Kip1</sup> , a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest," Genes Dev. 8:9-22 (1994a)		
	255.	POLYAK, K. et al., "Cloning of p27 <sup>Kip1</sup> , a Cyclin-dependent Kinase Inhibitor and a		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	34	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
		Potential Mediator of Extracellular Antimitogenic Signals," Cell 78:59-66 (1994b)		
	256.	PURI, P.L. et al., in STEIN et al., eds., "The Intrinsic Cell Cycle: From Yeast to Mammals," <u>The molecular basis of cell cycle and growth control</u> , Wiley & Sons Inc., pp.15 - 79		
	257.	QIU, M. et al., "Molecular Cloning and Expression of Human Grap-2, a Novel Leukocyte-Specific SH2- and SH3-Containing Adaptor-like Protein That Binds to Gab-1," Biochem.Biohphs. Res. Commun. 253:443-447 (1998)		
	258.	QUEEN, C. and BALTIMORE, D., "Immunoglobulin Gene Transcription Is Activated by Downstream Sequence Elements," Cell 33:741-748 (1983)		
	259.	QUELLE, D.E. et al., "Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts," Genes Dev. 7:1559-1571 (1993)		
	260.	RADEVA, G. et al., "Overexpression of the Integrin-linked Kinase Promotes Anchorage-independent Cell Cycle Progression," J. Biol. Chem. 272:13937-13944 (1997)		
	261.	REED, S.I., "Control of the G1/S Transition," Cancer Surv. 29:7-23 (1997)		
	262.	RESNITZKY, D. and REED, S.I., "Different Roles for Cyclins D1 and E in Regulation of the G1-to-S Transition," Mol. Cell Biol. 15:3463-3469 (1995)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	35	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	263.	RESNITZKY, D. et al., "Cyclin A-Associated Kinase Activity Is Rate Limiting for Entrance into S Phase and Is Negatively Regulated in G1 in p27 <sup>Kip1</sup> ," Mol. Cell Biol. 15:4347-4352 (1995)	
	264.	RESNITZKY, D. et al., "Acceleration of the G1/S Phase Transition by Expression of Cyclins D1 and E with an Inducible System," Mol. Cell Biol. 14:1669-1679 (1994)	
	265.	REYNISDOTTIR, I. and MASSAGUE, J., "The subcellular locations of p15 <sup>Ink4b</sup> and p27 <sup>Kip1</sup> coordinate their inhibitory interactions with cdk4 and cdk2," Genes Dev. 11:492-503 (1997)	
	266.	RICH, D.P. et al., "Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells," Nature 347:358-363 (1990)	
	267.	RIVARD, N. et al., "Abrogation of p27 <sup>Kip1</sup> by cDNA Antisense Suppresses Quiescence (G <sub>0</sub> State) in Fibroblasts," J. Biol. Chem. 271:18337-18341 (1996)	
	268.	RIVAS, G. and MINTON, A.P., "New developments in the study of biomolecular associations via sedimentation equilibrium," Trends Biochem. Sci. 18:284-287 (1993)	
	269.	RODIER, G. et al., "p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis," EMBO J. 20:6672-6682 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	36	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	270.	ROGINSKAYA, V. et al., "Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth," Leukemia 13:855-861 (1999)	
	271.	ROSENBERG, S.A. et al, "Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction," N. Engl. J. Med. 323:570-578 (1990)	
	272.	ROSENBERG, S.A. et al., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report," N. Engl. J. Med. 319:1676-1680 (1988)	
	273.	ROSENBERG, S.A. et al., "A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes," Science 233:1318-1321 (1986)	
	274.	ROSSIG, L. et al., "Akt-Dependent Phosphorylation of p21 <sup>Cip1</sup> Regulates PCNA Binding and Proliferation of Endothelial Cells," Mol. Cell Biol. 21:5644-5657 (2001)	
	275.	ROUSSEL, M.F., "The INK4 family of cell cycle inhibitors in cancer," Oncogene 18:5311-5317 (1999)	
	276.	ROZAKIS-ADCOCK, M. et al., "The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1," Nature 363:83-85 (1993)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	37	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	277.	RUSSO, A.A. et al., "Crystal structure of the p27 <sup>Kip1</sup> cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex," Nature 382:325-331 (1996a)		
	278.	RUSSO, A.A. et al., "Structural basis of cyclin-dependent kinase activation by phosphorylation," Nat. Struct. Biol. 3:696-700 (1996b)		
	279.	RUSSO, A.A. et al., "Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16 <sup>INK4a</sup> ," Nature 395:237-243 (1998)		
	280.	SAHA, P. et al., "p21 <sup>Cip1</sup> and Cdc25A: Competition between an Inhibitor and an Activator of Cyclin-Dependent Kinases," Mol. Cell Biol. 17:4338-4345 (1997)		
	281.	SANGER, F. et al., "DNA sequencing with chain-terminating inhibitors," PNAS USA 74:5463-5467 (1977)		
	282.	SCHULTZ, L.D. et al., "Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus," Gene 54:113-123 (1987)		
	283.	SCOTT, J.K. and SMITH, G.P., "Searching for Peptide Ligands with an Epitope Library," Science 249:386-390 (1990)		
	284.	SCOTT, M.T. et al., "Reversible Phosphorylation at the C-terminal Regulatory Domain of p21 <sup>Waf1/Cip1</sup> Modulates Proliferating Cell Nuclear Antigen Binding," J. Biol. Chem.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	38	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		275:11529-11537 (2000)	
	285.	SEED, B., "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2," Nature 329:840-842 (1987)	
	286.	SEOANE, J. et al., "TGF $\beta$ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15 <sup>INK4b</sup> ," Nat. Cell Biol. 3:400-408 (2001)	
	287.	SERRANO, M. et al., "Role of the INK4a Locus in Tumor Suppression and Cell Mortality," Cell 85:27-37 (1996)	
	288.	SHEAFF, R.J. et al., "Cyclin E-CDK2 is a regulator of p27 <sup>Kip1</sup> ," Genes Dev. 11:1464-1478 (1997)	
	289.	SHERR, C.J. and ROBERTS, J.M., "CDK inhibitors: positive and negative regulators of G1-phase progression," Genes Dev. 13:1501-1512 (1999)	
	290.	SHERR, C.J., "Cancer Cell Cycles," Science 274:1672-1677 (1996)	
	291.	SHERR, C.J., "Mammalian G1 Cyclins," Cell 73:1059-1065 (1993)	
	292.	SJOLANDER, S. and URBANICZKY, C. "Integrated Fluid Handling System for Biomolecular Interaction Analysis," Anal. Chem. 63:2338-2345 (1991)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	39	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	293.	SKOLNIK, E.Y. et al., "The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling," EMBO J. 12:1929-1936 (1993)	
	294.	SLINGERLAND, J. and PAGANO, M., "Regulation of the Cdk Inhibitor p27 and Its Dereglulation in Cancer," J. Cell Physiol. 183:10-17 (2000)	
	295.	SLINGERLAND, J.M. et al., "A Novel Inhibitor of Cyclin-Cdk Activity Detected in Transforming Growth Factor $\beta$ -Arrested Epithelial Cells," Mol. Cell Biol. 14:3683-3694 (1994)	
	296.	SMITH, D.B. and JOHNSON, K.S., "Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase," Gene 67:31-40 (1988)	
	297.	SMITH, G.E. et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," Mol. Cell Biol. 3:2156-2165 (1983)	
	298.	SONENBERG, N. and GINGRAS, A.C., "The mRNA 5' cap-binding protein eIF4E and Control of cell growth," Curr. Opin. Cell Biol. 10:268-275 (1998)	
	299.	SORGE, J. et al., "Complete correction of the enzymatic defect of type I Gaucher disease fibroblasts by retroviral-mediated gene transfer," PNAS USA 84:906-909 (1987)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	40	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	300.	SPARKS, A.B. et al, "Distinct ligand preferences of Src homology 3 domains from Src, Yes, Abl, Cortactin, p53bp2, PLCγ, Crk, and Grb2," PNAS USA 93:1540-1544 (1996)	
	301.	SPIRIN, K.S. et al., "p27/Kip1 Mutation Found in Breast Cancer," Cancer Res. 56:2400-2404 (1996)	
	302.	SPRUCK, C. et al., "A CDK-Independent Function of Mammalian Cks1: Targeting of SCF <sup>Skp2</sup> to the CDK Inhibitor p27 <sup>Kip1</sup> ," Mol. Cell. 7:639-650 (2001)	
	303.	STEINER, P. et al., "Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes," EMBO J. 14:4814-4826 (1995)	
	304.	STOKOE, D. and MCCORMICK, F., "Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro," EMBO J. 16:2384-2396 (1997)	
	305.	STROHMAIER, H. et al., "Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line," Nature 413:316-322 (2001)	
	306.	STUDIER et al. in "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes," <u>Gene Expression Technology: Methods in Enzymology</u> , Vol. 85, Academic Press, San Diego, CA, 1991, pp. 60-89	
	307.	SUGIYAMA, Y. et al, "Direct Binding of the Signal-transducing Adaptor Grb2 Facilitates Down-regulation of the Cyclin-dependent Kinase Inhibitor p27 <sup>Kip1</sup> ," J. Biol.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	41	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Chem. 276:12084-12090 (2001)	
	308.	SUN, J. et al., "Role for p27Kip1 in Vascular Smooth Muscle Cell Migration," Circulation 103:2967-2972 (2001)	
	309.	SUTTERLUTY, H. et al., "p45 <sup>SKP2</sup> promotes p27 <sup>Kip1</sup> degradation and induces S phase in quiescent cells," Nat. Cell Biol. 1:207-214 (1999)	
	310.	SZABO, A. et al., "Surface plasmon resonance and its use in biomolecular interaction analysis (BIA)," Curr. Opin. Struct. Biol. 5:699-705 (1995)	
	311.	TAKIZAWA, C.G. and MORGAN, D.O., "Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C," Curr. Opin. Cell Biol. 12:658-665 (2000)	
	312.	TAKUWA, N. et al., "Cyclin D1 Expression Mediated by Phosphatidylinositol 3-Kinase through mTOR-p70 <sup>S6K</sup> -Independent Signaling in Growth Factor-Stimulated NIH 3T3 Fibroblasts," Mol. Cell Biol. 19:1346-1358 (1999)	
	313.	TAUTZ, D. and RENZ, M., "An Optimized Freeze-Squeeze Method for the Recovery of DNA Fragments from Agarose Gels," Anal. Biochem. 132:14-19 (1983)	
	314.	TOMODA, K. et al., "The Cytoplasmic Shuttling and Subsequent Degradation of p27Kip1 Mediated by Jab1/CSN5 and the COP9 Signalosome Complex," J. Biol.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	42	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		Chem. 277:2302-2310 (2002)	
	315.	TOMODA, K. et al., "Degradation of the cyclin-dependent-kinase inhibitor p27 <sup>Kip1</sup> is instigated by Jab1," Nature 398:160-165 (1999)	
	316.	TOYOSHIMA, F. et al., "Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint," EMBO J. 17:2728-2735 (1998)	
	317.	TOYOSHIMA, H. and HUNTER, T., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell 78:67-74 (1994)	
	318.	TSAI, L.H. et al., "Isolation of the human cdk2 gene that encodes the cyclin A-and adenovirus E1A-associated p33 kinase," Nature 353:174-177 (1991)	
	319.	TSVETKOV, L.M. et al., "p27 <sup>Kip1</sup> ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27," Curr. Biol. 9:661-664 (1999)	
	320.	TYERS, M. and JORGENSEN, P., "Proteolysis and the cell cycle: with this RING I do thee destroy," Curr. Opin. Genet.Dev. 10:54-64 (2000)	
	321.	VAN DER GEER, P. and HUNTER, T., "Mutation of Tyr697, a GRB2-binding site, and Tyr721, a PI 3-kinase binding site, abrogates signal transduction by the murine CSF-1 receptor expressed in Rat-2 fibroblasts," EMBO J. 12:5161-5172 (1993)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	43	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>	
	322.	VAN NESS, J. and CHEN, L., "The use of oligodeoxynucleotide probes in chaotrope-based hybridization solutions," Nucleic Acids Res. 19:5143-5151 (1991)		
	323.	VERBEEK, B.S. et al., "Grb2 Overexpression in Nuclei and Cytoplasm of Human Breast Cells: A Histochemical and Biochemical Study of Normal and Neoplastic Mammary Tissue Specimens," J. Pathol. 183:195-203 (1997)		
	324.	VIDAL, A. and KOFF, A., "Cell-cycle inhibitors: three families united by a common cause," Gene 247:1-15 (2000)		
	325.	VIGO, E. et al., "CDC25A Phosphatase Is a Target of E2F and Is Required for Efficient E2F-Induced S Phase," Mol. Cell Biol. 19:6379-6395 (1999)		
	326.	VLACH, J. et al., "Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27 <sup>Kip1</sup> ," EMBO J. 16:5334-5344 (1997)		
	327.	WADA, K. et al., "Codon usage tabulated from the GenBank genetic sequence data," Nucleic Acids Res. 20:2111-2118 (1992)		
	328.	WANG, Q.M. et al., "p53/56lyn Antisense Shifts the 1,25-Dihydroxyvitamin D3-Induced G1/S Block in HL60 Cells to S Phase," Cell Physiol. 183:238-246 (2000)		
	329.	WATSON, J.D. et al., eds., "Working Toward Human Gene Therapy," <u>Recombinant</u>		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	44	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
		<u>DNA</u> , 2 <sup>nd</sup> ed., Scientific American Books, NY, Chapter 28, pp. 567-581 (1992)		
	330.	WEI, N. et al., "The COP9 complex is conserved between plants and mammals and is related to the 26S proteasome regulatory complex," Curr. Biol. 8:919-922 (1998)		
	331.	WIENERT, T., "Yeast Checkpoint Controls and Relevance to Cancer," Cancer Surv. 29:109-132 (1997)		
	332.	WELCH, P.J. and WANG, J.Y., "A C-Terminal Protein-Binding Domain in the Retinoblastoma Protein Regulates Nuclear c-Abl Tyrosine Kinase in the Cell Cycle," Cell 75:779-790 (1993)		
	333.	WENG, L.P. et al., "PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model," Hum. Mol. Genet. 10:599-604 (2001)		
	334.	WINOTO, A. and BALTIMORE, D., "A novel, inducible and T cell-specific enhancer located at the 3' end of the T cell receptor $\alpha$ locus," EMBO J. 8:729-733 (1989)		
	335.	WINSTON, J.T. et al., "A family of mammalian F-box proteins," Curr. Biol. 9:1180-1182 (1999)		
	336.	WON, K.A. and REED, S.I., "Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E," EMBO J.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	45	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
		15:4182-4193 (1996)		
	337.	WONG, S. and WITTE, O.N., "The BCR-ABL Story: Bench to Bedside and Back," Annu. Rev. Immunol. 22:247-306 (2004)		
	338.	XAUS, J. et al., "Decorin inhibits macrophage colony-stimulating factor proliferation of macrophages and enhances cell survival through induction of p27 <sup>Kip1</sup> and p21 <sup>Waf1</sup> ," Blood 98:2124-2133 (2001)		
	339.	XIONG, Y. et al., "p21 is a universal inhibitor of cyclin kinases," Nature 366:701-704 (1993)		
	340.	YAN, Y. et al., "Ablation of the CDK inhibitor p57 <sup>Kip2</sup> results in increased apoptosis and delayed differentiation during mouse development," Genes Dev. 11:973-983 (1997)		
	341.	YANG, J. et al., "Control of Cyclin B1 localization through regulated binding of the nuclear export factor CRM1," Genes Dev. 12:2131-2143 (1998)		
	342.	YANG, W. et al., "Repression of transcription of the p27 <sup>Kip1</sup> cyclin-dependent kinase inhibitor gene by c-Myc," Oncogene 20:1688-1702 (2001)		
	343.	YAROSLAVSKIY, B.B. et al., "p27Kip1 localizes to Detergent-insoluble Microdomains Within Lymphocyte Membranes," Mol. Med. 7:49-58 (2001)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/576,845
				Filing Date	April 20, 2006
				First Named Inventor	Ludger Hengst et al.
				Art Unit	1652
				Examiner Name	Not Yet Assigned
Sheet	46	Of	47	Attorney Docket Number	33769-701.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	344.	YAUN, Z.M. et al, "Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-β-D-arabinofuranosylcytosine," Oncogene 13:939-946 (1996)	
	345.	ZACHARIAE, W. and NASMYTH, K., "Whose end is destruction: cell division and the anaphase-promoting complex," Genes Dev. 13:2039-2058 (1999)	
	346.	ZENG, Y. et al., "Minimal Requirements for the Nuclear Localization of p27Kip1, a Cyclin-Dependent Kinase Inhibitor," Biochem. Biophys. Res. Commun. 274:37-42 (2000)	
	347.	ZERVOS, A.S. et al, "Mx1, a Protein That Specifically Interacts with Max to Bind Myc-Max Recognition Sites," Cell 72:223-232 (1993)	
	348.	ZHANG, H. et al., "p-21-containing cyclin kinases exist in both active and inactive states," Genes Dev. 8:1750-1774 (1994)	
	349.	ZHANG, H. et al., "Proliferating Cell Nuclear Antigen and p21 Are Components of Multiple Cell Cycle Kinase Complexes," Mol. Biol. Cell 4:897-906 (1993)	
	350.	ZHANG, P. et al, "p21CIP1 and p57KIP2 control muscle differentiation at the myogenin step," Genes Dev. 13:213-224 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/576,845	
				Filing Date	April 20, 2006	
				First Named Inventor	Ludger Hengst et al.	
				Art Unit	1652	
				Examiner Name	Not Yet Assigned	
Sheet	47	Of	47	Attorney Docket Number		33769-701.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	351.	ZHANG, P. et al., "Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome," Nature 387:151-158 (1997)		
	352.	ZHENG, N. et al., "Structure of the Cul1-Rbx1-Skp1-F box <sup>Skp2</sup> SCF ubiquitin ligase complex," Nature 416:703-709 (2002)		
	353.	ZIEVE, G.W. et al., "Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole," Exp. Cell Res. 126:397-405 (1980)		
	354.	ZUCKERMANN, R.N. et al., "Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library," J. Med. Chem. 37:2678-2685 (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.